MORABITO, FORTUNATO
 Distribuzione geografica
Continente #
NA - Nord America 562
AS - Asia 551
EU - Europa 465
SA - Sud America 175
AF - Africa 14
OC - Oceania 1
Totale 1.768
Nazione #
US - Stati Uniti d'America 540
SG - Singapore 301
IT - Italia 269
CN - Cina 179
BR - Brasile 163
DE - Germania 59
FI - Finlandia 52
HK - Hong Kong 34
NL - Olanda 21
AT - Austria 16
RU - Federazione Russa 13
CA - Canada 12
UA - Ucraina 8
FR - Francia 6
GB - Regno Unito 6
TR - Turchia 6
AR - Argentina 5
JP - Giappone 5
BD - Bangladesh 4
CZ - Repubblica Ceca 4
IQ - Iraq 4
PA - Panama 4
PK - Pakistan 4
ZA - Sudafrica 4
ET - Etiopia 3
MX - Messico 3
DK - Danimarca 2
IN - India 2
KE - Kenya 2
KR - Corea 2
NO - Norvegia 2
NP - Nepal 2
PE - Perù 2
PL - Polonia 2
SC - Seychelles 2
SN - Senegal 2
AE - Emirati Arabi Uniti 1
BS - Bahamas 1
CH - Svizzera 1
CO - Colombia 1
DO - Repubblica Dominicana 1
EC - Ecuador 1
ES - Italia 1
GY - Guiana 1
IE - Irlanda 1
JM - Giamaica 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LB - Libano 1
LT - Lituania 1
MA - Marocco 1
MO - Macao, regione amministrativa speciale della Cina 1
NZ - Nuova Zelanda 1
OM - Oman 1
PH - Filippine 1
PT - Portogallo 1
UY - Uruguay 1
UZ - Uzbekistan 1
VE - Venezuela 1
Totale 1.768
Città #
Florence 154
Boardman 139
Singapore 133
Ashburn 75
Shanghai 42
Beijing 35
Helsinki 34
Hong Kong 33
Munich 25
Sesto Fiorentino 23
Noto 22
São Paulo 22
Washington 19
Los Angeles 18
The Dalles 15
Guangzhou 13
Milan 12
Ogden 11
Rio de Janeiro 11
Vienna 11
New York 10
Santa Clara 10
Turku 9
Wuhan 9
Lappeenranta 8
Amsterdam 7
Catania 7
Naaldwijk 7
Belo Horizonte 5
Brooklyn 5
Nuremberg 5
Rome 5
Tokyo 5
Falkenstein 4
Montreal 4
San Francisco 4
Secaucus 4
Addis Ababa 3
Ankara 3
Brasília 3
Denver 3
Palmi 3
Atlanta 2
Bari 2
Boston 2
Campinas 2
Caxias do Sul 2
Curitiba 2
Dakar 2
Enfield 2
Erbil 2
Forlì 2
Frankfurt am Main 2
Gualdo Tadino 2
Guarulhos 2
Hangzhou 2
Jinhua 2
Johannesburg 2
Karachi 2
La Plata 2
Maceió 2
Mexico City 2
Nairobi 2
Naples 2
Olomouc 2
Oslo 2
Phoenix 2
Piracicaba 2
Recife 2
Ribeirão Preto 2
Seattle 2
Seoul 2
Shenzhen 2
Teresina 2
Toronto 2
Turin 2
Uberlândia 2
Votorantim 2
West Jordan 2
Wuxi 2
Agadir 1
Agudo 1
Alexandria 1
Allentown 1
Almaty 1
Alzano Lombardo 1
Amparo 1
Andaraí 1
Antalya 1
Aparecida de Goiânia 1
Aracaju 1
Aracati 1
Aragarças 1
Araçuaí 1
Arujá 1
Atibaia 1
Auckland 1
Augusta 1
Barnaul 1
Barra do Garças 1
Totale 1.066
Nome #
Dissecting the Biological Relevance and Clinical Impact of lncRNA MIAT in Multiple Myeloma 53
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 52
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 51
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 48
Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol 46
Genes selection using deep learning and explainable artificial intelligence for chronic lymphocytic leukemia predicting the need and time to therapy 46
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia 44
Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair? 44
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 43
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 42
Momelotinib in myelofibrosis 41
Elotuzumab in multiple myeloma 41
Selinexor in multiple myeloma 40
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 39
Belantamab mafodotin in multiple myeloma 39
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study 37
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 36
Myelodysplastic syndromes with ring sideroblasts 35
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 35
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study 34
MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cells 34
Iron chelation therapy 34
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 34
Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter? 34
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia 33
Teclistamab-cqyv in multiple myeloma 32
Human pluripotent stem cells identify molecular targets of trisomy 12 in chronic lymphocytic leukemia patients 29
Acalabrutinib in chronic lymphocytic leukemia 29
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials 28
Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature 28
Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities 27
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study 27
Glasdegib for the treatment of acute myeloid leukemia 26
LINC00152 expression in normal and Chronic Lymphocytic Leukemia B cells 25
MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective Study 25
Ivosidenib in acute myeloid leukemia 24
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma 24
Relapsed/Refractory Follicular Lymphoma: Current Advances and Emerging Perspectives 22
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort 22
Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications 21
REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA 21
Therapeutic Strategies for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients: Optimizing the Use of Monoclonal Antibodies 20
Zanubrutinib for the treatment of chronic lymphocytic leukemia 20
Isatuximab in multiple myeloma 19
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials 19
Advances and Challenges in Quizartinib‐Based FLT3 Inhibition for Acute Myeloid Leukemia: Mechanisms of Resistance and Prospective Combination Therapies 19
Transcriptomic Analysis in Multiple Myeloma and Primary Plasma Cell Leukemia with t(11;14) Reveals Different Expression Patterns with Biological Implications in Venetoclax Sensitivity 19
Safety and efficacy of caplacizumab in a case of thrombotic thrombocytopenic purpura in the postpartum period 18
Comparative Analysis of Bispecific Antibodies and CAR T‐Cell Therapy in Follicular Lymphoma 18
Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura 17
Therapy‐Related Acute Promyelocytic Leukemia: Case Series and Current Insights 17
Potential of BGB-1417, a BCL2 inhibitor, in hematological malignancies 17
The role of corticosteroids in the current treatment paradigm for myelofibrosis 16
Comparison of isatuximab-pomalidomide-dexamethasone versus elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data 16
Venetoclax in acute myeloid leukemia 16
Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens 16
TP53 Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia 15
TP53‐Mutated Acute Myeloid Leukemia: Unanswered Questions 15
Mosunetuzumab for the treatment of follicular lymphoma 15
Frailty predicts treatment-related toxicity and discontinuation in older adults with chronic lymphocytic leukemia treated with BTK and BCL-2 inhibitors: Findings from a prospective single-center cohort study 14
Avatrombopag for the Treatment of Immune Thrombocytopenia 14
Investigational CXCR4 inhibitors in early phase development for the treatment of hematological malignancies 13
Tagraxofusp in myeloid malignancies 13
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab‐, Elotuzumab‐, and Carfilzomib‐Based Triplet Regimens: A Multicenter Real‐World Analysis of 635 Patients 11
The potential of triplet combination therapies for patients with FLT3-ITD -mutated acute myeloid leukemia 11
Talquetamab in Multiple Myeloma: Efficacy, Safety, and Future Directions 11
Early progression beyond first‐line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study 10
Rilzabrutinib for the Treatment of Immune Thrombocytopenia 9
Totale 1.843
Categoria #
all - tutte 17.990
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.990


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202369 0 0 0 0 0 0 30 4 4 4 21 6
2023/2024599 9 14 121 91 53 90 29 21 20 10 21 120
2024/20251.175 56 112 33 72 68 63 32 67 220 143 146 163
Totale 1.843